EA201991443A1 - ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9 - Google Patents

ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9

Info

Publication number
EA201991443A1
EA201991443A1 EA201991443A EA201991443A EA201991443A1 EA 201991443 A1 EA201991443 A1 EA 201991443A1 EA 201991443 A EA201991443 A EA 201991443A EA 201991443 A EA201991443 A EA 201991443A EA 201991443 A1 EA201991443 A1 EA 201991443A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cas protein
relates
polypeptide
cas9 nucleases
genetic engineering
Prior art date
Application number
EA201991443A
Other languages
English (en)
Inventor
Джон Ван Дер Ост
Рихард Ван Краненбург
Эллеке Фенна Босма
Иоаннис Маугиакос
Original Assignee
Вагенинген Университейт
Стихтинг Вор Де Технише Ветенсхаппен
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вагенинген Университейт, Стихтинг Вор Де Технише Ветенсхаппен filed Critical Вагенинген Университейт
Publication of EA201991443A1 publication Critical patent/EA201991443A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/50Biochemical production, i.e. in a transformed host cell
    • C12N2330/51Specially adapted vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Термостабильные нуклеазы Cas9. Настоящее изобретение относится к области генной инженерии и, в частности, к редактированию нуклеиновых кислот и модификации генома. Настоящее изобретение относится к выделенному белку Cas или его полипептидному фрагменту, имеющему аминокислотную последовательность SEQ ID NO: 1 или последовательность, идентичную ей по меньшей мере на 77%. Белок или полипептид Cas способен к связыванию, расщеплению, маркированию или модификации двухцепочечного полинуклеотида-мишени при температуре в диапазоне от 30 до 100°C включительно. Изобретение также относится к выделенным молекулам нуклеиновой кислоты, кодирующим указанные нуклеазы Cas9, экспрессионным векторам и клеткам-хозяевам. По изобретению также предложены последовательности PAM, узнаваемые белком или полипептидом Cas. Нуклеазы Cas9, раскрытые в настоящем документе, являются новыми инструментами для генетической инженерии при повышенных температурах и имеют особую ценность при генетических манипуляциях с термофильными организмами, в частности микроорганизмами.
EA201991443A 2016-12-14 2016-12-14 ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9 EA201991443A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2016/081077 WO2018108272A1 (en) 2016-12-14 2016-12-14 Thermostable cas9 nucleases

Publications (1)

Publication Number Publication Date
EA201991443A1 true EA201991443A1 (ru) 2020-01-14

Family

ID=57755254

Family Applications (4)

Application Number Title Priority Date Filing Date
EA201991443A EA201991443A1 (ru) 2016-12-14 2016-12-14 ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9
EA201991442A EA201991442A1 (ru) 2016-12-14 2017-08-16 ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9
EA201991440A EA201991440A1 (ru) 2016-12-14 2017-08-16 ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9
EA201991441A EA201991441A1 (ru) 2016-12-14 2017-12-14 ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9

Family Applications After (3)

Application Number Title Priority Date Filing Date
EA201991442A EA201991442A1 (ru) 2016-12-14 2017-08-16 ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9
EA201991440A EA201991440A1 (ru) 2016-12-14 2017-08-16 ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9
EA201991441A EA201991441A1 (ru) 2016-12-14 2017-12-14 ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9

Country Status (11)

Country Link
US (5) US11242513B2 (ru)
EP (4) EP3555275A1 (ru)
JP (6) JP7182545B2 (ru)
KR (4) KR20190104342A (ru)
CN (4) CN110312792B (ru)
AU (4) AU2016432443B2 (ru)
BR (4) BR112019012155A2 (ru)
CA (4) CA3046824A1 (ru)
EA (4) EA201991443A1 (ru)
PH (4) PH12019501344A1 (ru)
WO (3) WO2018108272A1 (ru)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
CA2986310A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
JP7396783B2 (ja) 2015-06-09 2023-12-12 エディタス・メディシン、インコーポレイテッド 移植を改善するためのcrispr/cas関連方法および組成物
GB201510296D0 (en) * 2015-06-12 2015-07-29 Univ Wageningen Thermostable CAS9 nucleases
CA2999500A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
EP4269577A3 (en) 2015-10-23 2024-01-17 President and Fellows of Harvard College Nucleobase editors and uses thereof
WO2017165826A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
EP4047092A1 (en) 2016-04-13 2022-08-24 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
SG11201900907YA (en) 2016-08-03 2019-02-27 Harvard College Adenosine nucleobase editors and uses thereof
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CN110214180A (zh) 2016-10-14 2019-09-06 哈佛大学的校长及成员们 核碱基编辑器的aav递送
EA201991443A1 (ru) 2016-12-14 2020-01-14 Вагенинген Университейт ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
EP3592777A1 (en) 2017-03-10 2020-01-15 President and Fellows of Harvard College Cytosine to guanine base editor
CN110914426A (zh) 2017-03-23 2020-03-24 哈佛大学的校长及成员们 包含核酸可编程dna结合蛋白的核碱基编辑器
WO2018201086A1 (en) 2017-04-28 2018-11-01 Editas Medicine, Inc. Methods and systems for analyzing guide rna molecules
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
CN110997908A (zh) 2017-06-09 2020-04-10 爱迪塔斯医药公司 工程化的cas9核酸酶
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
GB201716590D0 (en) * 2017-10-10 2017-11-22 Univ Wageningen Thermostable cas9 nucleases with reduced off-target activity
JP2021500036A (ja) 2017-10-16 2021-01-07 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. アデノシン塩基編集因子の使用
KR102465067B1 (ko) * 2018-02-15 2022-11-10 시그마-알드리치 컴퍼니., 엘엘씨 진핵 게놈 변형을 위한 조작된 cas9 시스템
JP2022505440A (ja) 2018-11-01 2022-01-14 キージーン ナムローゼ フェンノートシャップ 植物細胞におけるCRISPR/Casゲノム編集のためのデュアルガイドRNA
AU2020221274B2 (en) 2019-02-15 2024-02-08 Sigma-Aldrich Co. Llc. Crispr/Cas fusion proteins and systems
BR112021018607A2 (pt) 2019-03-19 2021-11-23 Massachusetts Inst Technology Métodos e composições para editar sequências de nucleotídeos
CN112301018B (zh) * 2019-05-14 2023-07-25 深圳华大生命科学研究院 新型的Cas蛋白、Crispr-Cas***及其在基因编辑领域中的用途
US20220348939A1 (en) * 2019-07-30 2022-11-03 Hubei University CRISPR-Cas system for genome editing in Zymomonas mobilis, and applications thereof
CN110331158B (zh) * 2019-07-30 2021-09-14 湖北大学 基于运动发酵单胞菌内源CRISPR-Cas***的多基因位点同时编辑方法及其应用
WO2021032180A1 (zh) * 2019-08-21 2021-02-25 江南大学 一种多靶点编辑重组曲霉菌株的可视化筛选方法
US11879134B1 (en) * 2019-09-05 2024-01-23 The Regents Of The University Of Colorado, A Body Corporate Recombineering machinery to increase homology directed genome editing in thermophilic microbes
CN116096873A (zh) 2020-05-08 2023-05-09 布罗德研究所股份有限公司 同时编辑靶标双链核苷酸序列的两条链的方法和组合物
CN111778230A (zh) * 2020-07-17 2020-10-16 山东舜丰生物科技有限公司 一种适用于Cas12蛋白的缓冲***及其应用
RU2749307C1 (ru) * 2020-10-30 2021-06-08 Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт сельскохозяйственной биотехнологии" (ФГБНУ ВНИИСБ) Новая компактная нуклеаза CAS9 II типа из Anoxybacillus flavithermus
CN114480347B (zh) * 2022-02-21 2022-12-23 中国科学院地球化学研究所 一种纯化Cas12a蛋白的方法
CN114934031B (zh) * 2022-05-25 2023-08-01 广州瑞风生物科技有限公司 新型Cas效应蛋白、基因编辑***及用途
JP7152094B1 (ja) 2022-06-30 2022-10-12 リージョナルフィッシュ株式会社 tracrRNAユニット、及びゲノム編集方法
CN117701530A (zh) * 2022-12-08 2024-03-15 广州瑞风生物科技有限公司 Cas蛋白截短体、构建其的方法及其应用
CN116144631B (zh) * 2023-01-17 2023-09-15 华中农业大学 耐热型核酸内切酶及其介导的基因编辑***

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2176082B1 (es) 2000-05-31 2004-01-01 Consejo Superior Investigacion Bacterias con la capacidad de unir metales pesados y su empleo en la detoxificacion de medios contaminados con metales pesados.
US7220571B2 (en) 2000-09-28 2007-05-22 Archer-Daniels-Midland Company Escherichia coli strains which over-produce L-threonine and processes for the production of L-threonine by fermentation
WO2002066622A2 (en) * 2001-02-23 2002-08-29 Novozymes A/S Method of generating diversity into lipolytic enzymes and lipolytic enzyme genes
US7670807B2 (en) 2004-03-10 2010-03-02 East Tennessee State Univ. Research Foundation RNA-dependent DNA polymerase from Geobacillus stearothermophilus
JP2006230303A (ja) 2005-02-25 2006-09-07 Art Engineering Kk 好熱性リパーゼ産生菌およびその利用
KR100872695B1 (ko) 2006-11-27 2008-12-10 씨제이제일제당 (주) Gras 미생물로부터 발현된 식품안전형 호열성아라비노스 이성화효소 및 그를 이용한 타가토스의제조방법
KR101491867B1 (ko) * 2007-01-31 2015-02-10 피페넥스 인크. 증가된 발현을 위한 박테리아 리더 서열
WO2011041402A1 (en) 2009-09-29 2011-04-07 Butamax(Tm) Advanced Biofuels Llc Improved flux to acetolactate-derived products in lactic acid bacteria
MX362866B (es) 2012-05-25 2019-02-20 Univ California Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn.
RS63427B1 (sr) 2013-03-15 2022-08-31 Cibus Us Llc Postupci i kompozicije za povećanje efikasnosti modifikacije ciljnog gena korišćenjem genske reparacije posredovane oligonukleotidom
UA124375C2 (uk) 2014-03-14 2021-09-08 Кібус Юс Ллс Спосіб здійснення спрямованої генетичної зміни днк в клітині рослини з використанням нуклеази crispr і модифікованого gron
US10725041B2 (en) 2014-11-04 2020-07-28 Versiti Blood Research Institute Foundation, Inc. Method to bioengineer designer platelets using gene editing and stem cell methodologies
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
WO2016099887A1 (en) 2014-12-17 2016-06-23 E. I. Du Pont De Nemours And Company Compositions and methods for efficient gene editing in e. coli using guide rna/cas endonuclease systems in combination with circular polynucleotide modification templates
US20160346359A1 (en) * 2015-05-01 2016-12-01 Spark Therapeutics, Inc. Adeno-associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease
US20190136248A1 (en) * 2015-05-15 2019-05-09 Pioneer Hi-Bred International, Inc. Novel guide rna/cas endonuclease systems
GB201510296D0 (en) * 2015-06-12 2015-07-29 Univ Wageningen Thermostable CAS9 nucleases
EA201991443A1 (ru) 2016-12-14 2020-01-14 Вагенинген Университейт ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9

Also Published As

Publication number Publication date
CN110382693B (zh) 2024-04-09
EP3555278B1 (en) 2024-05-29
WO2018108272A1 (en) 2018-06-21
CN110431229B (zh) 2024-03-12
EA201991442A1 (ru) 2020-01-13
US20220213455A1 (en) 2022-07-07
AU2017377136A1 (en) 2019-07-11
CN110382693A (zh) 2019-10-25
KR20190104342A (ko) 2019-09-09
KR102523543B1 (ko) 2023-04-19
BR112019012173A2 (pt) 2019-11-05
US11939605B2 (en) 2024-03-26
WO2018108339A1 (en) 2018-06-21
CA3046842A1 (en) 2018-06-21
PH12019501335A1 (en) 2019-09-16
US20210340532A1 (en) 2021-11-04
KR20190104344A (ko) 2019-09-09
PH12019501344A1 (en) 2019-10-28
AU2017377135A1 (en) 2019-07-11
JP2020510410A (ja) 2020-04-09
EP3555276A1 (en) 2019-10-23
BR112019012165A2 (pt) 2019-11-12
JP7283698B2 (ja) 2023-05-30
CN110352241B (zh) 2024-04-09
BR112019012155A2 (pt) 2019-11-12
AU2017377792B2 (en) 2024-04-18
AU2017377135B2 (en) 2024-04-18
KR102662270B1 (ko) 2024-05-02
US20190322993A1 (en) 2019-10-24
US11242513B2 (en) 2022-02-08
CA3046828A1 (en) 2018-06-21
JP2020505000A (ja) 2020-02-20
US11326162B2 (en) 2022-05-10
AU2016432443A1 (en) 2019-07-11
EP3555275A1 (en) 2019-10-23
WO2018108338A1 (en) 2018-06-21
AU2017377792A1 (en) 2019-07-11
WO2018108339A9 (en) 2018-09-20
JP2020504603A (ja) 2020-02-13
US20190367893A1 (en) 2019-12-05
JP2020506667A (ja) 2020-03-05
CN110312792B (zh) 2024-04-09
US20190360002A1 (en) 2019-11-28
JP7223377B2 (ja) 2023-02-16
CN110312792A (zh) 2019-10-08
CN110352241A (zh) 2019-10-18
EA201991441A1 (ru) 2020-01-09
KR20190104343A (ko) 2019-09-09
CA3046824A1 (en) 2018-06-21
JP7223376B2 (ja) 2023-02-16
PH12019501340A1 (en) 2019-09-30
KR20190104345A (ko) 2019-09-09
EP3555278A1 (en) 2019-10-23
EA201991440A1 (ru) 2020-01-13
AU2017377136B2 (en) 2024-04-18
CA3046826A1 (en) 2018-06-21
US11976306B2 (en) 2024-05-07
JP2022166045A (ja) 2022-11-01
PH12019501346A1 (en) 2019-11-04
JP7182545B2 (ja) 2022-12-02
CN110431229A (zh) 2019-11-08
EP3555277A1 (en) 2019-10-23
BR112019012183A2 (pt) 2019-11-05
JP2022166170A (ja) 2022-11-01
AU2016432443B2 (en) 2024-04-18
KR102523544B1 (ko) 2023-04-19

Similar Documents

Publication Publication Date Title
EA201991442A1 (ru) ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9
PH12017502281A1 (en) Thermostable cas9 nucleases
CA3166153A1 (en) Base editors, compositions, and methods for modifying the mitochondrial genome
PH12021550904A1 (en) Novel crispr/cas12f enzyme and system
RU2022103603A (ru) Направляемые нуклеиновыми кислотами нуклеазы
JP6902052B2 (ja) 複数のリガーゼ組成物、システム、および方法
EA201892810A1 (ru) Гибридные последовательности нуклеиновых кислот для геномной инженерии
MX2022005328A (es) Composiciones y metodos para el reemplazo de alelos con adn codificado por arn.
RU2015112583A (ru) Функциональные локусы fad2 и соответствующие специфичные для сайта-мишени связывающиеся белки, способные индуцировать направленные разрывы
CN102757960B (zh) 一种扩增未知序列的半随机pcr技术及其引物和试剂盒
EA202190454A1 (ru) Новый crispr-ассоциированный белок и его применение
EP4279597A3 (en) Novel, non-naturally occurring crispr-cas nucleases for genome editing
SG11201809242VA (en) Method for increasing mutation introduction efficiency in genome sequence modification technique, and molecular complex to be used therefor
CA3228222A1 (en) Class ii, type v crispr systems
EP3129475B1 (en) Dna polymerases from the red sea brine pool organisms
WO2019204643A3 (en) Animal pathogen-derived polypeptides and uses thereof for genetic engineering
WO2018014799A1 (zh) 重组酶聚合酶扩增试剂盒、扩增方法及扩增试剂
Li et al. Clipping of predetermined fragments from the human genome by S1 nuclease–PNA combinations
Park et al. Group II Intron-Like Reverse Transcriptases Function in Double-Strand Break Repair by Microhomology-Mediated End Joining
CN107312788A (zh) 一种tale重复序列载体的构建方法
Ng Avoiding CRISPR: Plasmid design for genetic engineering
Ignatov et al. Novel small RNAs from Mycobacterium avium
Chan Transcriptome Analysis of Bacterial Response to Heat Shock Using Next‐Generation Sequencing
Pandey et al. A new method for the robust expression and single-step purification of dCas9 for CRISPR interference/activation (CRISPRi/a) applications
Selkova et al. Characterization of Streptococcus uberis Cas9 (SuCas9)-a Type II-A Ortholog Functional in Human Cells